Molecular landscape of non-squamous, non-small cell carcinoma of the lung
The treatment of advanced or metastatic non-small cell lung cancer (NSCLC) has undergone a major change over the past decade, from a single option of platinum-based systemic chemotherapy to an increasingly personalized approach to treatment based on specific molecular alterations within tumors. The scope of this paper is to review the literature on the treatment of non-squamous NSCLC and give a broad understanding of the current molecular targets for which therapies currently exist, as well as other targets for which therapies may soon be developed. Additionally, issues of resistance with targeted therapies will be discussed. This manuscript only summarizes the work done to date, and in no way is meant to be comprehensive.